Medicare seniors get easier access to non-opioid pain drugs, bypassing insurance gatekeeping
H.R. 1227 — Alternatives to PAIN Act · Filed by Mariannette Miller-Meeks (R-IA) · 110 cosponsors · Introduced Feb 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare Part D to make non-opioid pain management drugs more affordable and accessible by eliminating deductibles, placing them on the lowest cost-sharing tier, and prohibiting step therapy (requiring patients to try opioids first) and prior authorization delays. Starting January 1, 2026, qualifying non-opioid drugs—those FDA-approved for acute or postoperative pain, not acting on opioid receptors, and below a specialty-tier cost threshold—become easier for seniors to obtain without insurance barriers.
Why we flagged it
The bill's core mechanism is a regulatory mandate requiring Medicare Part D plans to cover non-opioid pain drugs at the lowest cost tier and without administrative barriers. It is not a subsidy or appropriation but a coverage requirement imposed on private insurers and MA-PD plans.
What the text implies
- The bill defines 'qualifying non-opioid pain management drugs' by reference to a 'monthly specialty-tier cost threshold as determined by Sec. from time to time'—the threshold-setting mechanism is not specified in the text, creating regulatory discretion that could narrow or broaden the drug class after passage.
- By prohibiting step therapy that requires opioid use first, the bill may increase non-opioid drug utilization among seniors, shifting demand away from opioids and toward alternative pain-management products—benefiting manufacturers of non-opioid alternatives (e.g., NSAIDs, biologics, novel analgesics) at the expense of opioid-dependent revenue streams.
The full analysis lists 5 implications of this text.
Who stands to gain
Non-opioid pain management drug manufacturers (e.g., biologics, NSAIDs, novel analgesics); Pharmaceutical companies with FDA-approved non-opioid pain products; Medicare beneficiaries (reduced out-of-pocket costs)